Hong Kong Tobacco Stock News

SEHK:1027
SEHK:1027Luxury

Asia Strategy Digit Technology Holdings Leads 3 Asian Penny Stocks To Monitor

As global markets navigate a complex landscape of economic resilience and inflationary pressures, the Asian market continues to capture investor interest with its diverse opportunities. Penny stocks, though an outdated term, remain relevant for those seeking growth potential in smaller or newer companies. By focusing on financial strength and growth prospects, investors can uncover compelling opportunities among these often-overlooked stocks.
SEHK:2209
SEHK:2209Specialty Retail

YesAsia Holdings And 2 Other Promising Penny Stocks In Global

Global markets have recently faced a mix of challenges, with U.S. stock indexes experiencing declines and economic data highlighting both resilience and inflationary pressures. Amid such volatility, investors often seek opportunities in smaller or newer companies that can offer unique growth prospects. Penny stocks, despite their somewhat outdated name, remain relevant as they represent these smaller entities; when backed by solid financial foundations, they can present valuable opportunities...
SEHK:6990
SEHK:6990Biotechs

A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After Positive 2026 ASCO Lung Cancer Data

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) drew fresh attention after the 2026 ASCO Annual Meeting, where it reported positive Phase III sac-TMT plus pembrolizumab data and pivotal Phase II lunbotinib results in non small cell lung cancer. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The recent ASCO data drops landed against a mixed trading backdrop, with the share price at HK$393.4 after a 1-day share price return of 0.82%. However, the 7-day share price...
SEHK:1541
SEHK:1541Biotechs

Asian Market Insights: ImmuneOnco Biopharmaceuticals (Shanghai) Among 3 Promising Penny Stocks

As global markets navigate a complex landscape of economic resilience and inflationary pressures, Asian equities have shown mixed performance amid these shifting dynamics. For investors interested in smaller or newer companies, penny stocks—despite the term's somewhat outdated nature—remain a compelling area for potential growth. These stocks, often characterized by their affordability and growth potential when supported by robust financials, can offer intriguing opportunities; this article...
SEHK:1651
SEHK:1651Machinery

Discover 3 Asian Companies That May Be Priced Below Their Estimated Value

As Asian markets navigate a landscape of mixed economic signals and geopolitical tensions, investors are increasingly focused on identifying opportunities that may be undervalued amidst the broader uncertainty. In this context, finding stocks that are priced below their estimated value can offer potential advantages, especially when considering factors such as resilience in specific sectors or strong fundamentals that could withstand regional volatility.
SEHK:3698
SEHK:3698Banks

Regina Miracle International Holdings And 2 Other Promising Small Caps In Asia

Amidst a backdrop of mixed global market performance, Asian small-cap stocks have captured investor attention as potential opportunities for growth and diversification. With the Russell 2000 Index showing notable year-to-date gains, investors are increasingly looking towards smaller companies that demonstrate resilience and innovation in challenging economic environments. Identifying promising small caps often involves focusing on firms with strong fundamentals, innovative business models,...
SEHK:1398
SEHK:1398Banks

A Look At ICBC (SEHK:1398) Valuation After Its RMB 60,000 Million Tier 2 Capital Notes Issuance

Industrial and Commercial Bank of China (SEHK:1398) has just completed a RMB 60,000 million Tier 2 capital notes issuance in the National Interbank Bond Market, a financing step aimed at strengthening its tier 2 capital position. See our latest analysis for Industrial and Commercial Bank of China. The HK$6.83 share price has a 1-day share price return of 1.64% and a 7-day share price return of 2.86%. The 1-year total shareholder return of 26.07% and 5-year total shareholder return of 104.62%...
SEHK:268
SEHK:268Software

Assessing Kingdee International Software Group’s Valuation After Governance Changes And Return To Net Income

Governance changes and recent financial recovery take center stage Kingdee International Software Group (SEHK:268) has drawn fresh attention after shareholders approved new amended and restated Articles of Association, together with the company’s recent shift from a net loss to net income in 2025. See our latest analysis for Kingdee International Software Group. Despite the recent governance changes and return to profitability, the share price has been under pressure, with the 1-year total...
SEHK:3388
SEHK:3388Tech

Assessing Shenzhen Creality 3D Technology (SEHK:3388) Valuation After Recent Share Price Weakness

Recent share price move puts Shenzhen Creality 3D Technology in focus A sharp one day move has put Shenzhen Creality 3D Technology (SEHK:3388) on investors’ radar, with the stock falling about 9% in the latest session and roughly 8% year to date. With a market value of about HK$9.8b and reported revenue of CN¥3,127.04m against a net loss of CN¥182.561m, the company sits at an interesting point for investors assessing growth potential versus current profitability. See our latest analysis for...
SEHK:2269
SEHK:2269Life Sciences

Assessing WuXi Biologics (SEHK:2269) Valuation After Its Recent Share Price Momentum Shift

Recent share performance and company snapshot WuXi Biologics (Cayman) (SEHK:2269) has seen mixed share performance recently, with the stock edging up about 1% over the past day but declining around 10% over the past 3 months. The company runs an end to end biologics contract research, development, and manufacturing business, serving clients across North America, Europe, the People’s Republic of China, and other regions. It reported revenue of CN¥21,790.018 million and net income of...
SEHK:6990
SEHK:6990Biotechs

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

At the 2026 ASCO Annual Meeting, Sichuan Kelun-Biotech Biopharmaceutical reported past Phase III and Phase II data in NSCLC, including sacituzumab tirumotecan plus pembrolizumab showing longer progression-free survival than pembrolizumab alone and lunbotinib fumarate delivering high response rates in RET fusion-positive disease, alongside encouraging first-in-human results for its B7-H3 ADC SKB500. The inclusion of sacituzumab tirumotecan data in The Lancet and the acceptance of lunbotinib’s...
SEHK:1919
SEHK:1919Shipping

Assessing COSCO SHIPPING Holdings (SEHK:1919) Valuation After Dividend Approval And Leadership Changes

Leadership and dividend moves reshaping the picture for COSCO SHIPPING Holdings COSCO SHIPPING Holdings (SEHK:1919) has just combined a fresh round of leadership appointments with approval of its 2025 final dividend, a pairing that gives investors new information on both governance and cash returns. See our latest analysis for COSCO SHIPPING Holdings. The share price reaction has been strong around these announcements, with a 1-day share price return of 6.68% and a 7-day share price return of...